Physicians Choice (PhC).

DRUG2 trials

Sponsors

University Hospital Heidelberg, Prof. Wolfgang Janni

Conditions

Breast CancerMetastatic Colorectal Cancer

Phase 2

Sacituzumab Govitecan in Metastatic Colorectal Cancer

RecruitingNCT06243393

University Hospital HeidelbergMetastatic Colorectal Cancer

Start: 2024-04-19End: 2029-02-01Target: 80Updated: 2024-07-10

Phase 3

A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse

RecruitingNCT06643585

Prof. Wolfgang JanniBreast Cancer

Start: 2025-04-22End: 2032-04-22Target: 180Updated: 2025-05-02

Related Papers

Abstract PS5-07-28: The SURVIVE HERoes study NCT06643585: Targeting molecular relapse in breast cancer

Clinical Cancer Research2026-02-17

The SURVIVE HERoes study: Targeting molecular relapse in breast cancer—A secondary adjuvant intervention study of trastuzumab deruxtecan versus SOC treatment in patients with HER2-positive or HER2-low early breast cancer and ctDNA positivity after primary therapy.

Journal of Clinical Oncology2025-05-28